

# Participant Journey

This tool is to help you understand what to expect during the MPCT-021N study. More detail about each step can be found on the back of this sheet.



Up to 28 days

## 1. Sign Informed Consent Form and complete Screening

To join the study, you will need to read and sign the Informed Consent Form (ICF) and receive assessments to determine if you qualify (called Screening). Your study doctor will inform you if you need to decrease or stop your current medication during this period.



1 day

## 2. Enroll in study and undergo leukapheresis

If you are eligible for the study, you will complete a procedure called leukapheresis to collect some of your white blood cells, which will be used to create IMPT-514. Your study doctor will inform you if you need to decrease or stop your current medication during this period.

Approximately  
3 weeks

## Manufacture IMPT-514



5 days

## 3. Begin lymphodepleting therapy

Before your IMPT-514 infusion, you will have 3 days of lymphodepleting therapy, followed by 2 days of rest.



Approximately  
1 week

## 4. Receive IMPT-514 infusion and monitoring

You will be admitted to the hospital to receive an infusion of IMPT-514 and will remain in the hospital for at least 1 week.



1 year

## 5. Attend follow-up study visits

After you are discharged, you will return to see the study doctor regularly for study follow-up visits. For the first 28 days after your infusion, you will need to stay within 1 hour of the hospital with a caregiver present.



14 years

## 6. Enter long-term follow-up period

The study doctors will want to see you or contact you once a year through Year 15 after your infusion to monitor your health and safety.

## 1. Sign Informed Consent Form and complete Screening

- The Informed Consent Form (ICF) explains the study and what you can expect in more detail. Participation is your choice, but you are required to sign the ICF to give your consent before you receive IMPT-514 or assessments.
- After you sign the ICF, you will go through a Screening process to determine if you are able to enroll in the study. Screening assessments may include, but are not limited to, vital signs, blood tests, heart tests (ECG and ECHO), and a breathing test.

## 2. Enroll in study and undergo leukapheresis

- If you are eligible to join, you will complete a procedure called leukapheresis to collect some of your white blood cells. Leukapheresis takes about 4 to 6 hours.
- During leukapheresis, blood is removed through a needle in your arm and passed through a special machine called a blood separator. This machine collects your white blood cells and gives the rest of your blood back to you.
- During this period, your study doctor will inform you if you need to decrease or stop your current medication. If you have any symptoms of your disease that require medication, you may be re-started on some of your disease medications, but these may need to be decreased or stopped again prior to lymphodepleting therapy (step 3).

### Manufacture IMPT-514

- Your white blood cells will be used to develop the study drug, IMPT-514, which is unique to you.
- Your white blood cells will be sent to a manufacturing facility to be genetically modified and grown. They will be stored at the manufacturing facility until they are approved to be released and you are ready to receive them. The cells are thoroughly examined and tested to ensure they meet rigorous quality standards before release. This process takes approximately 3 weeks.

## 3. Begin lymphodepleting therapy

- About 5 days before your IMPT-514 infusion, you will begin lymphodepleting therapy. You will receive 3 days of medication as an IV infusion, followed by 2 days of rest. This medication helps prepare your body to receive IMPT-514.
- You will also receive other assessments, such as vital signs, blood tests, and questionnaires.

## 4. Receive IMPT-514 infusion and monitoring

- You will be admitted to the hospital to receive IMPT-514 as an infusion into your vein. IMPT-514 will consist of your white blood cells that were collected during leukapheresis and modified in a lab to identify and potentially kill the disease-causing cells.
- You will remain in the hospital for at least 7 days after the infusion for observation.
- During your hospital stay, the study staff will check on you regularly. You will also receive assessments similar to others received throughout the study. The exact date of release from the hospital will be determined by your study doctor.

## 5. Attend follow-up study visits

- After you are discharged, you will return to see the study doctor regularly for study follow-up visits. During follow-up visits, you will receive more assessments, which help study staff measure how your body is responding to IMPT-514.
- Four of these visits will happen within 28 days (about 1 month) of receiving your IMPT-514 infusion. **It is important that you remain within 1 hour of travel to the hospital for these visits, in case you experience any side effects.** If you need to stay overnight near the hospital, you will be reimbursed. You will also monitor your blood pressure, heart rate, oxygen, and temperature using equipment the study staff provides to you.
- After 28 days, you will have 7 more follow-up visits through Month 12.

## 6. Enter long-term follow-up period

- About 1 year after your IMPT-514 infusion, you will enter the long-term follow-up period. During this period, federal regulations require the study doctors to see you or contact you once a year through Year 15 to monitor your health and safety.

**IMPACT** BIO